SCHEMBL8669797

SCHEMBL8669797

[c]1c(C2CC2)cc2ccccc2c1C1CC1

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.34
▸ CYP1B1 Q16678 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ HIF1A Q16665 1/20 0.34
▸ POLB P06746 2/20 0.33
▸ TSHR P16473 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ TRPM4 Q8TD43 1/20 0.31
▸ CYP1A2 P05177 2/20 0.31
▸ CYP2A6 P11509 2/20 0.31
▸ HTR2A P28223 1/20 0.31
▸ NQO2 P16083 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.30
▸ CYP1A1 P04798 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15515330 0.80 CYP1B1 (0.33) ALDH1A1CYP1B1HSD17B10HIF1APOLB
SCHEMBL458943 0.69 ALDH1A1 (0.37) ALDH1A1CYP1B1HSD17B10HIF1APOLB
SCHEMBL456160 0.67 DRD2 (0.33) —
SCHEMBL4720998 0.63 ALDH1A1 (0.32) ALDH1A1HSD17B10HIF1ATDP1
SCHEMBL458139 0.63 — —
SCHEMBL11409161 0.62 CYP1B1 (0.39) ALDH1A1CYP1B1HSD17B10HIF1ATSHR
SCHEMBL16752251 0.61 AKR1C3 (0.31) —
SCHEMBL21359041 0.60 NQO2 (0.53) ALDH1A1CYP1B1HSD17B10HIF1APOLB
SCHEMBL23071386 0.59 MAPT (0.34) CYP1B1POLBMAPTL3MBTL1TDP1
SCHEMBL31496254 0.59 POLB (0.45) ALDH1A1CYP1B1HSD17B10HIF1APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5811422-A USEFUL FOR TREATING VIRAL INFECTIONS THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-09-22 — — US disclosed
US-5610294-A VIRAL TREATMENT THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-03-11 — — US disclosed
Send feedback